A Study of the ILB-3101 in Patients with Advanced Solid Tumors
ConditionAdvanced Solid Tumor
Trial statusRecruiting
Trial phasePhase 1
Trial typeInterventional
Biological sexAll
Age18-80
SponsorInnolake Biopharm
About this trial
ILB-3101 is a fully humanized IgG1 antibody-drug conjugate (ADC) which specifically binds to B7-H3, a target wildly expressed on solid tumor cells. The objectives of this study are to investigate the safety, tolerability, pharmacokinetics and anti-tumor activity of ILB-3101 in Chinese advanced solid tumor patients.
Eligibility criteria
Qualifiers
Have signed informed consent forms voluntarily.
18-80 years old.
Having an ECOG performance status score of 0 or 1.
With an expected survival of more than 12 weeks.
Disqualifiers
Received urea nitrite or mitomycin C within 6 weeks prior to the first use of the study drug.
Oral administration of fluorouracil or small molecule targeted drugs within 2 weeks prior to the first use of the investigational drug or within 5 half-lives of the drug (whichever is longer).
Individuals who have received endocrine therapy within 2 weeks prior to the first use of the investigational drug.
Traditional Chinese patent medicines and simple preparations or traditional Chinese medicine with anti-tumor indication within 1 week before the first use of the study drug.
Trial design
Treatments tested in this trial
- ILB-3101
Treatment groups
240 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov